Orlistat treatment of Obese type 2 Diabetes
Expert Opin Pharmacother. 2010 Aug;11(12):1971-82.
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D’Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
University of Pavia, Department of Internal Medicine and Therapeutics, 27100 Pavia, Italy. firstname.lastname@example.org
AIM: To evaluate the effects of 1-year treatment with orlistat compared with placebo on different inflammatory parameters in type 2 obese diabetic patients.
MATERIALS AND METHODS: Two hundred and fifty-four type 2 diabetic patients were randomized to take orlistat 120 mg three times a day or placebo for 12 months. We evaluated at baseline and after 3, 6, 9 and 12 months: leptin, tumor necrosis factor (TNF)-alpha, adiponectin (ADN), vaspin and high-sensitivity C-reactive protein (HS-CRP), body weight, waist circumference, body mass index (BMI), lipid profile, glycemic profile, fasting plasma insulin (FPI) and homeostasis model assessment insulin resistance index (HOMA-IR).
RESULTS: Regarding inflammatory parameters, there was a significant improvement of ADN and TNF-alpha, and a faster decrease of leptin and HS-CRP in the orlistat group compared with the control group. We also recorded a significant reduction of body weight and BMI with orlistat, but not with placebo. A faster improvement of glycemic profile and FPI was obtained with orlistat compared with the controls. Also, there was a significant reduction of lipid profile with orlistat, not reached with placebo.
CONCLUSIONS: Orlistat was more effective than placebo in ameliorating inflammatory parameters such as ADN and TNF-alpha, and anthropometric parameters.
PMID: 20569086 [PubMed – indexed for MEDLINE]